GlassScriptPhysician profile
Krista Furman
NPI 1316643893
$1,808.59
in general payments reported to CMS, 2019-2025
25 companies · $744 in 2025
The $744 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $86.80 · 2024: $978 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,808.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $346.70 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $242.93 | 2024-2025 | Rybelsus, Ozempic, Tresiba |
| Pfizer INC. | $207.74 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $190.42 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $168.11 | 2023-2025 | |
| Axsome Therapeutics, INC. | $82.05 | 2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $69.65 | 2024-2025 | Veozah |
| Lundbeck LLC | $60.18 | 2024 | Vyepti |
| Bayer Healthcare Pharmaceuticals INC. | $49.86 | 2023-2025 | |
| Corium, LLC | $41.64 | 2023-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $30.24 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $28.85 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $28.84 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $28.28 | 2024-2025 | Voquezna |
| Inari Medical, INC. | $27.90 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $25.19 | 2025 | Inspire |
| Amgen INC. | $25.13 | 2025 | Krystexxa |
| Actelion Pharmaceuticals US, INC. | $25.10 | 2025 | Uptravi, Opsumit |
| Insulet Corporation | $22.08 | 2025 | Omnipod |
| Vanda Pharmaceuticals INC. | $20.93 | 2025 | Hetlioz, Fanapt |
| Otsuka America Pharmaceutical, INC. | $20.85 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $19.44 | 2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $18.03 | 2024 | Arexvy, Trelegy Ellipta |
| Shield Therapeutics INC | $14.66 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.79 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Furman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.